Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Merck KGaA (EMD Serono)

Status: Completed

Conditions: Relapsing Multiple Sclerosis

Treatments: Other: Other: Disease modifying therapies (DMT); Drug: Rebif

Study type: Observational

Funder types: Industry

Identifiers

NCT01601119

EMR200136_550

Details and patient eligibility

About

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Enrollment: 545 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsing Multiple Sclerosis patients aged 18 years or over.
• Naive to previous DMT therapy and not yet started treatment with a disease modifying therapy.

Exclusion criteria

• Participating in an MS-related clinical trial.
• Unwilling to provide electronic online consent.
• Any disability that may impair them from being able to complete the online questionnaire.
• Do not have regular access to the Internet.
• Unable to complete the baseline questionnaire before they receive their first DMT injection.

Trial design

545 participants in 2 patient groups

Rebif cohort

Description:

Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.

Treatment:

Drug: Rebif

Other DMT cohort

Description:

Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.

Treatment:

Other: Other: Disease modifying therapies (DMT)